-$10.2M
Net Activity
Institutions Holding
41
Popularity Rank
#6495
Avg Weight
0.04%
Total Value
$16.0M
41 institutions currently hold GANX, with 17 net buyers and 26 net sellers this quarter.
Institutional Moves (Q1 2026)
Majority Decreased
Based on recent trading activity
Net Selling Institutions
26
Net Buying Institutions
17
Top 5 by Value
+$7.0M
Total Buy Value
$10.5M
Total Sell Value
17
Net Buyers
26
Net Sellers
No Form 144 planned sale filings in the last 90 days
No Schedule 13D/13G filings for this ticker
1
Filings (14d)
Gain Therapeutics issued a press release and shareholder letter on July 16, 2026, stating that its current cash and equivalents are expected to fund operations into the second quarter of 2027. This guidance includes completing a Phase 1b open-label extension in October 2026 and starting a Phase 2 clinical study in the third quarter of 2026.
View Full Filing (SEC EDGAR)The most-added stocks by 13F institutions this quarter
Institutions Holding
6,150
Total reported value
$2.1T
3245 13F institutions increased their position this quarter
Institutions Holding
5,957
Total reported value
$1.5T
3028 13F institutions increased their position this quarter
Institutions Holding
5,764
Total reported value
$3.0T
2743 13F institutions increased their position this quarter